{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:11:45Z","timestamp":1791472305854,"version":"4.3.4"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2020.0452","type":"journal-article","created":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T16:31:19Z","timestamp":1583425879000},"page":"e200452","source":"Crossref","is-referenced-by-count":92,"title":["Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens"],"prefix":"10.1001","volume":"3","author":[{"given":"Lucia C.","family":"Petito","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts"},{"name":"Now with the Feinberg School of Medicine, Division of Biostatistics, Department of Preventive Medicine, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xabier","family":"Garc\u00eda-Alb\u00e9niz","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts"},{"name":"Mongan Institute, Massachusetts General Hospital, Boston"},{"name":"RTI Health Solutions, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger W.","family":"Logan","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Howlader","sequence":"additional","affiliation":[{"name":"Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela B.","family":"Mariotto","sequence":"additional","affiliation":[{"name":"Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issa J.","family":"Dahabreh","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts"},{"name":"Center for Evidence Synthesis in Health, Brown University, Providence, Rhode Island"},{"name":"Department of Health Services, Policy and Practice, Brown University, Providence, Rhode Island"},{"name":"Department of Epidemiology, Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Hern\u00e1n","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts"},{"name":"Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts"},{"name":"Harvard-MIT Health Sciences and Technology, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2020,3,5]]},"reference":[{"issue":"16","key":"zoi200035r1","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1200\/JCO.2017.72.6414","article-title":"Untapped potential of observational research to inform clinical decision making: American Society of Clinical Oncology Research Statement.","volume":"35","author":"Visvanathan","year":"2017","journal-title":"J Clin Oncol"},{"issue":"27","key":"zoi200035r2","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1056\/NEJM199912303412706","article-title":"Underrepresentation of patients 65 years of age or older in cancer-treatment trials.","volume":"341","author":"Hutchins","year":"1999","journal-title":"N Engl J Med"},{"issue":"22","key":"zoi200035r3","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","article-title":"Participation in cancer clinical trials: race-, sex-, and age-based disparities.","volume":"291","author":"Murthy","year":"2004","journal-title":"JAMA"},{"issue":"4","key":"zoi200035r4","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmaco-epidemiology.","volume":"167","author":"Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"issue":"8","key":"zoi200035r5","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available.","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"key":"zoi200035r6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","article-title":"Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses.","volume":"79","author":"Hern\u00e1n","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"zoi200035r7","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/EDE.0b013e3181875e61","article-title":"Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease.","volume":"19","author":"Hern\u00e1n","year":"2008","journal-title":"Epidemiology"},{"issue":"10","key":"zoi200035r8","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1038\/s41591-019-0597-x","article-title":"Avoidable flaws in observational analyses: an application to statins and cancer.","volume":"25","author":"Dickerman","year":"2019","journal-title":"Nat Med"},{"issue":"1","key":"zoi200035r9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jamaoncol.2017.2752","article-title":"Examining bias in studies of statin treatment and survival in patients with cancer.","volume":"4","author":"Emilsson","year":"2018","journal-title":"JAMA Oncol"},{"issue":"8","key":"zoi200035r10","first-page":"IV-3","article-title":"Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.","volume":"40","author":"Warren","year":"2002","journal-title":"Med Care"},{"issue":"5","key":"zoi200035r11","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s10120-017-0693-x","article-title":"Comparative effectiveness of adjuvant chemoradiotherapy after gastrectomy among older patients with gastric adenocarcinoma: a SEER-Medicare study.","volume":"20","author":"Yeh","year":"2017","journal-title":"Gastric Cancer"},{"issue":"11","key":"zoi200035r12","doi-asserted-by":"publisher","first-page":"e616","DOI":"10.1016\/j.clml.2019.08.014","article-title":"Comparative effectiveness of chemotherapy, rituximab, and bendamustine in Medicare beneficiaries with mantle-cell lymphoma.","volume":"19","author":"Fu","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"zoi200035r13","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/bjh.2016.175.issue-5","article-title":"Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes.","volume":"175","author":"Zeidan","year":"2016","journal-title":"Br J Haematol"},{"issue":"9604","key":"zoi200035r14","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1016\/S0140-6736(07)61866-2","article-title":"Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.","volume":"370","author":"Gray","year":"2007","journal-title":"Lancet"},{"issue":"15","key":"zoi200035r15","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.","volume":"25","author":"Moore","year":"2007","journal-title":"J Clin Oncol"},{"issue":"8","key":"zoi200035r17","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/j.1524-4733.2009.00600.x","article-title":"Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report\u2014part I.","volume":"12","author":"Berger","year":"2009","journal-title":"Value Health"},{"issue":"8","key":"zoi200035r18","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"issue":"7","key":"zoi200035r19","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.jclinepi.2010.10.004","article-title":"A combined comorbidity score predicted mortality in elderly patients better than existing scores.","volume":"64","author":"Gagne","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"zoi200035r20","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1097\/MLR.0000000000000122","article-title":"Validation of disability status, a claims-based measure of functional status for cancer treatment and outcomes studies.","volume":"52","author":"Davidoff","year":"2014","journal-title":"Med Care"},{"issue":"2","key":"zoi200035r21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jgo.2012.12.005","article-title":"A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes.","volume":"4","author":"Davidoff","year":"2013","journal-title":"J Geriatr Oncol"},{"issue":"9","key":"zoi200035r22","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1093\/jnci\/djj159","article-title":"Completion of therapy by Medicare patients with stage III colon cancer.","volume":"98","author":"Dobie","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"zoi200035r23","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10654-017-0287-2","article-title":"The value of explicitly emulating a target trial when using real world evidence: an application to colorectal cancer screening.","volume":"32","author":"Garc\u00eda-Alb\u00e9niz","year":"2017","journal-title":"Eur J Epidemiol"},{"issue":"25","key":"zoi200035r24","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1200\/JCO.2010.34.3426","article-title":"Adjuvant chemotherapy for stage II colon cancer with poor prognostic features.","volume":"29","author":"O\u2019Connor","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"zoi200035r25","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1245\/s10434-014-3631-8","article-title":"Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: analysis of SEER-Medicare data.","volume":"21","author":"Weiss","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"zoi200035r26","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.jpainsymman.2017.12.335","article-title":"Chemotherapy use, end-of-life care, and costs of care among patients diagnosed with stage IV pancreatic cancer.","volume":"55","author":"Bao","year":"2018","journal-title":"J Pain Symptom Manage"},{"issue":"14","key":"zoi200035r29","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1056\/NEJMsm1605385","article-title":"Per-protocol analyses of pragmatic trials.","volume":"377","author":"Hern\u00e1n","year":"2017","journal-title":"N Engl J Med"},{"key":"zoi200035r30","doi-asserted-by":"publisher","first-page":"k182","DOI":"10.1136\/bmj.k182","article-title":"How to estimate the effect of treatment duration on survival outcomes using observational data.","volume":"360","author":"Hern\u00e1n","year":"2018","journal-title":"BMJ"},{"issue":"5","key":"zoi200035r31","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/01.ede.0000135174.63482.43","article-title":"A structural approach to selection bias.","volume":"15","author":"Hern\u00e1n","year":"2004","journal-title":"Epidemiology"},{"issue":"1","key":"zoi200035r32","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cmpb.2003.10.004","article-title":"Adjusted survival curves with inverse probability weights.","volume":"75","author":"Cole","year":"2004","journal-title":"Comput Methods Programs Biomed"},{"issue":"5","key":"zoi200035r33","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology.","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"issue":"3","key":"zoi200035r34","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2307\/2529360","article-title":"On the treatment of grouped observations in life studies.","volume":"33","author":"Thompson","year":"1977","journal-title":"Biometrics"},{"issue":"12","key":"zoi200035r35","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study.","volume":"9","author":"D\u2019Agostino","year":"1990","journal-title":"Stat Med"},{"issue":"4","key":"zoi200035r36","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1097\/EDE.0b013e3181df1b69","article-title":"Estimating absolute risks in the presence of nonadherence: an application to a follow-up study with baseline randomization.","volume":"21","author":"Toh","year":"2010","journal-title":"Epidemiology"},{"issue":"8","key":"zoi200035r37","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1200\/JCO.2015.62.0294","article-title":"Inferring the effects of cancer treatment: divergent results from early breast cancer trialists\u2019 collaborative group meta-analyses of randomized trials and observational data from SEER registries","volume":"34","author":"Henson","year":"2016","journal-title":"J Clin Oncol"},{"issue":"27","key":"zoi200035r38","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1200\/JCO.2016.69.0875","article-title":"Retraction.","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi200035r39","first-page":"288","article-title":"NCI SEER public-use data: applications and limitations in oncology research.","volume":"23","author":"Yu","year":"2009","journal-title":"Oncology (Williston Park)"},{"issue":"11","key":"zoi200035r40","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Limits of observational data in determining outcomes from cancer therapy.","volume":"112","author":"Giordano","year":"2008","journal-title":"Cancer"},{"issue":"14","key":"zoi200035r41","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1200\/JCO.18.01074","article-title":"Comparison of population-based observational studies with randomized trials in oncology.","volume":"37","author":"Soni","year":"2019","journal-title":"J Clin Oncol"},{"key":"zoi200035r42","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jclinepi.2019.10.012","article-title":"Nonrandomized studies using causal-modeling may give different answers than RCTs: a meta-epidemiological study.","volume":"118","author":"Ewald","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"zoi200035r16","unstructured":"National Cancer Institute: Division of Cancer Control and Population Sciences. SEER-Medicare linked database. https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/. Published 2018. Accessed January 20, 2020."},{"key":"zoi200035r27","unstructured":"SEER-Medicare Technical Support, Information Management Services. Documentation for the Patient Entitlement and Diagnosis Summary File (PEDSF). https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/aboutdata\/PEDSF.pdf. Published December 2018. Accessed January 20, 2020."},{"key":"zoi200035r28","unstructured":"National Cancer Institute: Division of Cancer Control and Population Sciences. Measures that are limited or not available in the data. https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/considerations\/measures.html. Accessed January 20, 2020."}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2762046\/petito_2020_oi_200035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T15:00:56Z","timestamp":1586185256000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2762046"}},"subtitle":["Emulating Hypothetical Target Trials in the Surveillance, Epidemiology, and End Results (SEER)\u2013Medicare Linked Database"],"short-title":[],"issued":{"date-parts":[[2020,3,5]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.0452","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,5]]}}}